natgillin/translations-raw huggingface dataset:
The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels.
Dodatek posakonazola med zdravljenjem z atazanavirjem oziroma zatazanavirjem inritonavirjemje bilpovezan s povečanjemkoncentracijebilirubina vplazmi.
Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC04
Farmakoterapevtska skupina: antimikotiki za sistemsko zdravljenje, derivati triazola.
Posaconazole tablet and oral suspension safety
Varnost tablet in peroralne suspenzije posakonazola
Both doses of posaconazole increased Cmax and AUC of oral midazolam (2 mg single oral dose) by 2.2 and 4.5-fold, respectively.
Oba odmerkaposakonazola sta povečala Cmaxperoralno uporabljenegamidazolama (enkratniperoralni odmerek 2 mg) za 2,2-krat in njegovo AUC za 4,5-krat.
The pharmacokinetics of posaconazole oral suspension have been evaluated in paediatric patients.
Pri pediatričnih bolnikih so ocenili farmakokinetiko peroralne suspenzije posakonazola.
Phenytoin (200 mg once a day) decreased the Cmax and AUC of posaconazole by 41% and 50%, respectively.
Fenitoin(200 mg enkrat na dan) je zmanjšalCmaxposakonazola za 41 %, njegovo AUC paza
Clinically significant interactions resulting in hospitalisation and/or posaconazole discontinuation were reported in clinical efficacy studies.
V študijah klinične učinkovitosti so poročali o kliničnopomembnihinterakcijah, ki so zahtevale sprejem v bolnišnico in/ali ukinitev posakonazola.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Posaconazole Accord.
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom ali farmacevtom, preden začnete jemati zdravilo Posakonazol Accord.
Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4).
Sočasna uporaba azolskih antimikotikov, vključno s posakonazolom, in vinkristina je bila povezana zresnimineželenimi učinki (glejte poglavje
Due to the risk of prolonged sedation and possible respiratory depression co-administration of posaconazole with any benzodiazepines metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should only be considered if clearly necessary.
Zaradi tveganja pojava dolgotrajne sedacije in morebitne depresije dihanja lahko sočasna uporaba posakonazola in katerega koli benzodiazepina, ki se presnavlja s CYP3A4 (npr. midazolam,
Breast-feeding must be stopped on initiation of treatment with posaconazole.
Ob uvedbi zdravljenja s posakonazolom je treba prenehati zdojenjem.
There are currently insufficient data to set clinical breakpoints for Aspergillus spp.
Trenutno ni dovolj podatkov za določitev kliničnih mejnih vrednosti zaAspergillus spp.Vrednosti ECOFF niso enake kliničnim mejnim vrednostim.
paresthesia, dizziness, somnolence, headache, dysgeusia
parestezija, omotica, zaspanost, glavobol, disgevzija
The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole.
dni in s flukonazolom 77 dni.
Glucose concentrations decreased in some healthy volunteers when glipizide was co-administered with posaconazole.
Med sočasno uporabo glipizida in posakonazola se je pri nekaterih zdravih prostovoljcih znižala koncentracija glukoze.
Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed.
Posakonazol v obtoku nimanobenegaglavnegapresnovkainniverjetno,dabizaviralciencimov CYP450 vplivali nanjegovokoncentracijo.Odpresnovkov v obtoku je večina glukuronidnihkonjugatov posakonazola, opazili pa so le majhne količine oksidativnih presnovkov (presnova posredovana s CYP450).
thrombocytopenia, leukopenia, anaemia, eosinophilia, lymphadenopathy, splenic infarction
trombocitopenija, levkopenija, anemija, eozinofilija,
There is no special treatment available in the case of overdose with posaconazole.
V primeru prevelikega odmerjanja posakonazola ni na voljo nobenega posebnega zdravljenja.
Cases of elevated ciclosporin levels resulting in serious adverse reactions, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported in clinical efficacy studies.
V študijah klinične učinkovitosti so poročali o primerihpovečane koncentracije ciklosporina, ki je povzročila resne neželene učinke, vključno znefrotoksičnostjo in enim smrtnim primerom levkoencefalopatije.
pyrexia (fever), asthenia, fatigue
pireksija (zvišana telesna temperatura), astenija, utrujenost
The primary efficacy endpoint was the incidence of proven/probable IFIs at 16 weeks post-randomization as determined by an independent, blinded external expert panel.
Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanihoziromaverjetnihinvazivnihglivnihokužb16tednovporandomizaciji,kijih jeugotavljalaneodvisna skupina zunanjih strokovnjakov na slep način.
Frequent monitoring for adverse reactions and toxicity related to calcium channel blockers is recommended during co-administration with posaconazole.
Medsočasnouporabo s posakonazolom je priporočljivo pogosto spremljanje gledeneželenihučinkovin toksičnosti, povezanih z zaviralci kalcijevih kanalčkov.
Q3
QTc.
Tell your doctor if you are or think you are pregnant before you start to take Posaconazole Accord.
Če ste noseči ali menite, da bi lahko bili noseči, se posvetujte z zdravnikom, preden vzamete zdravilo Posakonazol Accord.
Liver function tests should be evaluated at the start of and during the course of posaconazole therapy.
Testedelovanjajeterje treba opraviti na začetku zdravljenja s posakonazolom in med zdravljenjem z njim.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below.
PosakonazoljemočanzaviralecCYP3A4.SočasnauporabaposakonazolainsubstratovCYP3A4lahko zelo poveča izpostavljenost tem substratom, kot kažejo spodaj opisani učinki na takrolimus, sirolimus,
Pulmonary phospholipidosis resulting in dilatation and obstruction of the alveoli was observed in the 2-year study in rats.
V2-letni študiji na podganah so opažali pljučno fosfolipidozo, ki je povzročila dilatacijo inobstrukcijo alveolov.
Following a single dose administration of 300 mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC0-72 hours and Cmax were higher compared to administration under fasted condition (51% and 16% for AUC0-72 hours and Cmax respectively).
Po enkratnem odmerku 300 mgposakonazola v tabletahpozelomastnemobrokustabiliprizdravihprostovoljcih AUC0-72urinCmaxvečji kotpouporabi natešče (AUC0-72 ur51%in Cmax16%).
H2 receptor antagonists and proton pump inhibitors No clinically relevant effects were observed when posaconazole tablets are concomitantly used with antacids, H2-receptor antagonists and proton pump inhibitors.
Antagonistireceptorjev H2in zaviralci protonske črpalke Medsočasno uporabo tablet posakonazola in antacidov, antagonistov receptorjev H2inzaviralcevprotonskečrpalkenisoopazilikliničnopomembnihučinkov.Med sočasno uporabo tabletposakonazolain antacidov, antagonistov receptorjev H2in zaviralcev protonske črpalkeprilagoditevodmerka tablet posakonazola ni potrebna.
Talk to your doctor or pharmacist before taking Posaconazole Accord - if you have had an allergic reaction to another antifungal medicine such as ketoconazole,
- če ste imeli alergijsko reakcijo na kakšno drugo protiglivno zdravilo, npr. na ketokonazol,
Gastro-resistant tablet
FARMACEVTSKA OBLIKA gastrorezistentna tableta
Hepatic reactions (e.g. mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin and/or clinical hepatitis) have been reported during treatment with posaconazole.
Med zdravljenjem s posakonazolom so poročali o učinkih na jetra (npr. blago do zmerno zvišanje ALT, AST, alkalne fosfataze, celokupnega bilirubina in/ali klinični hepatitis).
There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea).
Motnje v delovanju prebavil Zabolnike s hudimi motnjami v delovanju prebavil (npr. s hudo drisko) je na voljo malofarmakokinetičnih podatkov.
Fixed-time periodc
Določenočasovno obdobjec
Steady-state plasma concentrations are attained by Day 6 at the 300 mg dose (once daily after twice daily loading dose at Day 1).
Plazemska koncentracija v stanjudinamičnega ravnovesja je dosežena do 6. dne pri uporabi 300 mgodmerka(enkrat na dan pozačetnem odmerku dvakrat na dan 1. dan).
No effects on electrocardiograms, including QT and QTc intervals, were seen in a repeat dose safety pharmacology study in monkeys at maximal plasma concentrations 8.5-fold greater than the concentrations obtained at therapeutic doses in humans.
V farmakološki študiji varnosti ponavljajočih se odmerkov na opicah pri največjih koncentracijah v plazmi,kisobile8,5-krat večje od koncentracij, doseženih med uporabo terapevtskih odmerkov pričloveku, na elektrokardiogramih (vključno zintervaloma QT in QTc) niso opazili nobenih učinkov.
rash, pruritis
izpuščaj, pruritus
Do not take Posaconazole Accord if you are pregnant unless you are told to by your doctor.
Če ste noseči, ne jemljite zdravila Posakonazol Accord, razen če vam to naroči zdravnik.
If you get any side effects, talk to your doctor or pharmacist or nurse.
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom ali farmacevtom ali medicinsko sestro.
Neutropenia
nevtropenija
No overall differences in safety were observed between the geriatric patients and younger patients; therefore, no dosage adjustment is recommended for geriatric patients.
V celoti niso ugotovilirazlik v varnostimedgeriatričnimibolnikiinmlajšimi bolniki,zatogeriatričnimbolnikomodmerka ni treba prilagoditi.
In another study in healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to 7.6-fold), respectively.
(200 mg dvakrat na dan7dni) povečala Cmaxintravensko uporabljenegamidazolama(enkratni odmerek 0,4 mg) v povprečju za 1,3-krat, njegovo AUC pa za 4,6-krat (razpon od 1,7-kratdo 6,4krat).Peroralnasuspenzijaposakonazola v odmerku400mgdvakratnadan 7dni je povečalaCmaxintravenskouporabljenegamidazolamaza1,6-krat in njegovo AUC za 6,2-krat (razpon od 1,6-krat do 7,6-krat).
Similarly, in the prophylaxis studies, the mean steady-state posaconazole average concentration (Cav)
Podobno je bila v študijah profilaktične uporabe povprečna koncentracija posakonazola v stanju dinamičnega ravnovesja
Based on Kaplan-Meier estimates, the probability of survival up to day 100 after randomization, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P=0.0354) as well as IFI-related deaths (P = 0.0209).
Napodlagi Kaplan-Meierjevihocenjebilaverjetnostpreživetjado 100. dne po randomizaciji značilnovečja pri bolnikih, ki so prejemali posakonazol.Takoristenvplivnapreživetjesodokazali,koso vanaliziupoštevalivsevzrokesmrti(p = 0,0354), pa tudi smrti, povezane z invazivno glivno okužbo(p =
torsade de pointes, sudden death, ventricular tachycardia, cardio-respiratory arrest, cardiac failure, myocardial infarction
torsades de pointes, nenadna smrt, ventrikularna tahikardija, zastoj srca in dihanja, srčno popuščanje,
When initiating treatment with posaconazole in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three quarters of the current dose).
Na začetku zdravljenja s posakonazolom je treba bolnikom, ki že prejemajo ciklosporin, odmerek ciklosporina zmanjšati
Caution is advised during coadministration of posaconazole with CYP3A4 substrates administered intravenously and the dose of the CYP3A4 substrate may need to be reduced.
je potrebna previdnost in po potrebi zmanjšanje odmerka substrata CYP3A4.
Repeat dose administration of posaconazole oral suspension (400 mg twice daily for 16 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 6.7-fold and 8.9-fold (range 3.1 to 17.5-fold), respectively, in healthy subjects.
Uporaba večkratnih odmerkov posakonazola vobliki peroralne suspenzije (400 mg dvakrat na dan16 dni) je pri zdravih osebah (kiso dobile enkraten odmerek 2 mgsirolimusa) povečala Cmaxsirolimusa v povprečju za 6,7-kratinAUCsirolimusa v povprečjuza8,9-krat (razpon od 3,1-krat do17,5-krat).
Safety data at higher exposure levels achieved with posaconazole tablets are at present limited.
Trenutno je na voljo malo podatkov o varnosti pri večji izpostavljenosti zdravilu po uporabi posakonazola v obliki tablet.
If you take more Posaconazole Accord than you should If you think that you may have taken too much Posaconazole Accord, talk to a doctor or go to the hospital straight away.
Če menite, da ste vzeli preveč zdravila Posakonazol Accord, se takoj posvetujte z zdravnikom ali pojdite v bolnišnico.
These medicines include: - vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer) - ciclosporin (used during or after transplant surgery) - tacrolimus and sirolimus (used during or after transplant surgery) - rifabutin (used to treat certain infections) - medicines used to treat HIV called protease inhibitors (including lopinavir and atazanavir,
- vinkristin, vinblastin in drugi alkaloidi vinke (uporabljajo se za zdravljenje raka), - ciklosporin (uporablja se med ali po presaditvah), - takrolimus in sirolimus (uporabljata se med ali po presaditvah),
There is no paediatric experience with posaconazole tablets.
Pediatrična populacija Izkušenj s tabletami posakonazolapri pediatričnih bolnikih ni.
If you are not sure, talk to your doctor or pharmacist before taking Posaconazole Accord.
Če ste negotovi, se posvetujtezzdravnikom ali farmacevtom, preden vzamete zdraviloPosakonazol Accord.
NAME OF THE MEDICINAL PRODUCT Posaconazole Accord 100 mg gastro-resistant tablets
IME ZDRAVILA PosakonazolAccord 100 mg gastrorezistentne tablete
Controla
Kontrolnaskupinaa
Posaconazole Accord can be used in adults to treat the following types of fungal infections when other antifungal medicines have not worked or you have had to stop taking them: - infections caused by fungi of the Aspergillus family that have not improved during treatment with the anti-fungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped; - infections caused by fungi of the Fusarium family that have not improved during treatment with amphotericin B or when amphotericin B has had to be stopped; - infections caused by fungi that cause the conditions known as “chromoblastomycosis” and “mycetoma” that have not improved during treatment with itraconazole or when itraconazole has had to be stopped; - infections caused by a fungus called Coccidioides that have not improved during treatment with one or more of amphotericin B, itraconazole or fluconazole or when these medicines have had to be stopped.
- okužb,kijihpovzročajogliveiz družine Aspergillus in ki se niso izboljšale med zdravljenjem sprotiglivnima zdraviloma amfotericin B ali itrakonazol, ali če je bilo treba ti dve zdraviliukiniti; - okužb,kijihpovzročajogliveiz družine Fusariumin ki se niso izboljšale med zdravljenjem zamfotericinom B, ali če je bilo treba amfotericin B ukiniti;
Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients.
Plazemskekoncentracijeposakonazola se lahko po uporabi tablet pri nekaterih bolnikih sčasomapovečajo.
Tell your doctor or pharmacist or nurse straight away if you notice any of the following serious side effects - you may need urgent medical treatment: - nausea or vomit (feeling or being sick), diarrhoea - signs of liver problems - these include yellowing of your skin or whites of the eyes, unusually dark urine or pale faeces, feeling sick for no reason, stomach problems, loss of appetite or unusual tiredness or weakness, an increase in liver enzymes shown up in blood tests - allergic reaction.
- znakitežav z jetri;mednjimi so porumenelost kože ali očesnih beločnic, nenavadno temen urinalisvetloblato,slabost v želodcubrezrazloga,težave z želodcem,izguba apetita ali nenavadnautrujenost ali šibkost, zvišanje jetrnih encimov (pokaže se na preiskavah krvi) - alergijska reakcija
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS PERFORATED UNIT DOSE BLISTER
PERFORIRAN PRETISNI OMOT ZA ENKRATNI ODMEREK
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see sections 4.4 and 4.5).
pimozidom,halofantrinomalikinidinom,kerlahkopovečaplazemske koncentracije tehzdravil,karpalahkopovzroči podaljšanje intervala QTc in redko tudi torsades de pointes(glejte poglavji 4.4 in 4.5).
Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during coadministration with posaconazole.
Medsočasno uporabo posakonazola jepriporočljivo pogosto spremljanje glede neželenih učinkov intoksičnosti, povezanih s protiretrovirusnimi zdravili, ki so substrati CYP3A4.
Uncommon: the following may affect up to 1 in 100 people - anaemia - signs include headaches, feeling tired or dizzy, being short of breath or looking pale and a low level of haemoglobin shown up in blood tests - low level of platelets (thrombocytopenia) shown in blood tests - this may lead to bleeding - low level of “leukocytes” a type of white blood cell (leukopenia) shown in blood tests - this can make you more likely to get infections - high level of “eosinophils” a type of white blood cell (eosinophilia) - this can happen if you have inflammation - inflammation of the blood vessels - heart rhythm problems - fits (convulsions) - nerve damage (neuropathy) - abnormal heart rhythm - shown up on a heart trace (ECG), palpitations, slow or fast heartbeat,
Občasni: pojavijo se lahko pri največ 1 od 100 oseb - anemija - med znaki so glavoboli, utrujenost ali omotičnost, kratka sapa ali bledica ter nizka koncentracija hemoglobina, ki se pokaže na preiskavah krvi - nizko število trombocitov (trombocitopenija), ki se pokaže na preiskavah krvi - povzroči lahko krvavitve - nizko število levkocitov - belih krvnih celic (levkopenija) - pokaže se na preiskavah krvi;
The external control group included 86 patients treated with available therapy (as above) mostly at the same time and at the same sites as the patients treated with posaconazole.
(kot navedeno zgoraj), večinoma ob istem času in na istih mestih kot bolniki, zdravljeni s posakonazolom.
Following co-administration of posaconazole oral suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold respectively.
Po 7-dnevni sočasni uporabi peroralne suspenzijeposakonazola (400 mg dvakrat na dan) z atazanavirjem (300 mg enkrat na dan)se je pri zdravihpreiskovancihCmaxatazanavirja povečala v povprečjuza 2,6-krat, njegova AUC paza 3,7-krat
which are given with ritonavir) - midazolam, triazolam, alprazolam or other “benzodiazepines” (used as sedatives or muscle relaxants) - diltiazem, verapamil, nifedipine, nisoldipine or other “calcium channel blockers” (used to treat high blood pressure) - digoxin (used to treat heart failure) - Glipizide or other “sulfonylureas” (used to treat high blood sugar).
- diltiazem, verapamil, nifedipin, nizoldipin in drugi zaviralci kalcijevih kanalčkov (uporabljajo se za zdravljenje visokega krvnega tlaka),
After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function.
Po enkratnem peroralnem odmerku 400 mg peroralne suspenzije posakonazola pri bolnikih z blago(razred A po Child-Pughu), zmerno (razred B po Child-Pughu) ali hudo okvaro jeter (razred C
Oral posaconazole suspension 800 mg/day in divided doses was evaluated for the treatment of invasive aspergillosis in patients with disease refractory to amphotericin B (including liposomal formulations) or itraconazole or in patients who were intolerant of these medicinal products in a noncomparative salvage therapy trial (Study 0041).
V neprimerjalnem preskušanju (študija 0041) zadnje možnosti zdravljenja so za zdravljenje invazivneaspergilozepribolnikih z okužbo,odpornonaamfotericin B (vključno z liposomskimioblikami)aliitrakonazol, oziroma pri bolnikih, ki niso prenašali teh zdravil, ovrednotili peroralno suspenzijoposakonazola800 mg/dan v deljenih odmerkih.
Co-administration of posaconazole and ergot alkaloids is contraindicated (see section 4.3).
Sočasna uporaba posakonazola in alkaloidov ergot je kontraindicirana
Neuronal phospholipidosis occurred in dogs dosed for ≥ 3 months at lower systemic exposures than those obtained at therapeutic doses in humans.
Pri psih, ki so ≥ 3 mesece dobivali odmerke zdravila za manjšo sistemsko izpostavljenost od tiste,
Posaconazole Accord 100 mg gastro-resistant tablets posaconazole
Posakonazol Accord 100 mg gastrorezistentne tablete
Based on average Cmin concentrations, a predicted average concentration (Cav) could be calculated for 186 subjects dosed with 300 mg. PK analysis in patients of Cav found that 81% of the subjects treated with the 300 mg once daily dose attained steady state predicted Cav between 500-2,500 ng/mL.
preiskovancev, zdravljenih z odmerkom 300 mg enkrat na dan, doseglo predvideno Cav v stanjudinamičnega ravnovesja od 500 do 2.500 ng/ml.
The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient.
Učinek sočasne uporabe posakonazola na plazemske koncentracije substratov CYP3A4selahkorazlikujetudipriposameznembolniku.
Thereafter blood levels of tacrolimus should be monitored carefully during co-administration, and upon discontinuation of posaconazole, and the dose of tacrolimus should be adjusted as necessary.
Potem je treba natančno spremljati koncentracijotakrolimusa v krvi, in sicer med sočasno uporabo in po prenehanju zdravljenja s posakonazolom; odmerek takrolimusa jetrebaprilagoditi,kotjepotrebno.
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates) Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated.
Terfenadin, astemizol, cisaprid, pimozid, halofantrin in kinidin (substrati CYP3A4)
Posaconazole Accord contain sodium
Zdravilo Posakonazol Accord vsebuje natrij
Therefore, trough concentrations that fall in the upper part of the usual therapeutic range should be targeted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies.
Zaradi tega lahko najnižja koncentracija sirolimusa, ki je še v običajnemterapevtskemrazponu,dejansko pomeni koncentracijo, nižjo odterapevtske.Zatomora biti ciljna najnižja koncentracija sirolimusa v zgornjem delu običajnega terapevtskega razpona inposebnopozornostjetrebanamenitikliničnimznakominsimptomom,laboratorijskimparametromin tkivnim biopsijam.
It is, therefore, suggested to closely monitor for breakthrough fungal infections in patients weighing more than 120 kg.
Zato je bolnike, ki tehtajo več kot120 kg, priporočljivo skrbno spremljati glede prebijajočih glivnih okužb.
In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days) increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83%.
V študiji pri zdravih prostovoljcih je peroralna suspenzija posakonazola (200 mg enkrat na dan10 dni)